Pathologic upstaging in resected pancreatic adenocarcinoma: Risk factors and impact on survival

Elizabeth J. Olecki, Kelly A. Stahl, Madeline B. Torres, June S. Peng, Chan Shen, Matthew E.B. Dixon, Niraj J. Gusani

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Background: Clinical and pathologic staging determine treatment of pancreatic cancer. Clinical stage has been shown to underestimate final pathologic stage in pancreatic cancer, resulting in upstaging. Methods: National Cancer Database was used to identify clinical stage I pancreatic adenocarcinoma. Univariate, multivariable logistic regression, and Cox proportional hazard ratio were used to determine differences between upstaged and stage concordant patients. Results: Upstaging was seen in 80.2% of patients. Factors found to be significantly associated with upstaging included pancreatic head tumors (OR 2.56), high-grade histology (OR 1.74), elevated Ca 19-9 (OR 2.09), and clinical stage T2 (OR 1.99). Upstaging was associated with a 45% increased risk of mortality compared to stage concordant disease (HR 1.44, p <.001). Conclusion: A majority of clinical stage I pancreatic cancer is upstaged after resection. Factors including tumor location, grade, Ca 19-9, and tumor size can help identify those at high risk for upstaging.

Original languageEnglish (US)
Pages (from-to)79-87
Number of pages9
JournalJournal of Surgical Oncology
Issue number1
StatePublished - Jul 1 2021

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology


Dive into the research topics of 'Pathologic upstaging in resected pancreatic adenocarcinoma: Risk factors and impact on survival'. Together they form a unique fingerprint.

Cite this